0001689375-23-000044.txt : 20230623 0001689375-23-000044.hdr.sgml : 20230623 20230623162025 ACCESSION NUMBER: 0001689375-23-000044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230621 FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WENTWORTH KORY JAMES CENTRAL INDEX KEY: 0001725663 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40969 FILM NUMBER: 231037965 MAIL ADDRESS: STREET 1: 6 TIDE STREET STREET 2: C/O ENTRADA THERAPEUTICS CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entrada Therapeutics, Inc. CENTRAL INDEX KEY: 0001689375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813983399 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 17-500 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-305-1825 MAIL ADDRESS: STREET 1: ONE DESIGN CENTER PLACE STREET 2: SUITE 17-500 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: CycloPorters, Inc. DATE OF NAME CHANGE: 20161104 4 1 wf-form4_168755161282030.xml FORM 4 X0407 4 2023-06-21 0 0001689375 Entrada Therapeutics, Inc. TRDA 0001725663 WENTWORTH KORY JAMES C/O ENTRADA THERAPEUTICS, INC. ONE DESIGN CENTER PLACE, SUITE 17-500 BOSTON MA 02210 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-06-21 4 M 0 17500 2.10 A 45457 D Common Stock 2023-06-21 4 S 0 8593 14.8399 D 36864 D Common Stock 2023-06-21 4 S 0 8907 15.1711 D 27957 D Stock Option (Right to Buy) 2.1 2023-06-21 4 M 0 17500 0 D 2030-11-10 Common Stock 17500.0 83447 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $15.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Jared Cohen, as Attorney-in-Fact 2023-06-23